nephrotic syndrome protein losing illness
Conditions
Interventions
Five patients will receive 20 mg amiloride orally on two consecutive days and
receive 150 mg alirocumab as a subcutaneous
injection on the third day, and five patients will only receive 150 mg
evolo
Sponsors
Rijnstate Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Presence of heavy proteinuria (>3.5g/24h) - Presence of hypoalbuminemia (3.0 mmol/L) - Age >=18 years
Exclusion criteria
Exclusion criteria: - Use of immunosuppressive drugs - Estimated glomerular filtration rate (eGFR) of 5.0 mmol/L - Blood pressure of
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter is serum LDL cholesterol | — |
Secondary
| Measure | Time frame |
|---|---|
| ENaC activity assessed by urine Na/K ratio | — |
Countries
Netherlands
Outcome results
None listed